Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Renal Cell 22Carcinoma, Hepatocellular 7Kidney Neoplasms 6Osteosarcoma 5Sarcoma, Ewing 4Neoplasm Metastasis 4Sarcoma 3Clear-cell metastatic renal cell carcinoma 3Recurrence 2Prostatic Neoplasms 2Neuroendocrine Tumors 2Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Adrenocortical Carcinoma 2von Hippel-Lindau Disease 1Wilms Tumor 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Urachal adenocarcinoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sjogren's Syndrome 1Scleroderma, Systemic 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Refractory Differentiated Thyroid Gland Carcinoma 1

Interventions

pembrolizumab 1olaparib 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1cabozantinib 1Specimen Handling 1Mesna 1Magnetic Resonance Spectroscopy 1Floxuridine 1Dexamethasone 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Adrenal Cortex Neoplasms × cabozantinib × Clear all
NCT06006013 2026-02-18

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Emory University

Phase 2 Recruiting
21 enrolled
Endocrine

Adrenal Cortex Neoplasms, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡